Natural Capsules Limited (NSE:NATCAPSUQ) released a press release on August 13, 2026, pursuant to Regulation 30 of SEBI LODR Regulations, disclosing unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, with revenue of Rs 4.87 crore and EBITDA margins of 2.30%.
Key Highlights
- Revenue for Q1FY27 stood at Rs 4.87 crore, reflecting a 17% decline quarter-on-quarter and an 8% increase year-on-year as disclosed in the press release.
- EBITDA for the quarter was Rs 1.12 crore, with EBITDA margins at 2.30%, down 28 basis points quarter-on-quarter but up 159 basis points year-on-year.
- The company recorded a loss after tax of Rs 5.74 crore for Q1FY27, compared to a loss of Rs 5.55 crore in the preceding quarter, per the press release.
- One HPMC manufacturing line has been temporarily converted to a gelatine line, with a second conversion expected in the coming month, to optimise capacity utilisation.
About the Company
Natural Capsules Limited (NSE:NATCAPSUQ), incorporated in 1993 and headquartered in Bangalore, is a hard capsule shell manufacturer. The company operates manufacturing units in Attibele, Bangalore, and Pondicherry. It is the second-largest Indian manufacturer of gelatine capsules and pioneered vegetarian capsule manufacturing in India. It is now expanding into active pharmaceutical ingredient manufacturing through its subsidiary, Natural Biogenex Private Limited.
Announcement in Detail
The press release, filed under Regulation 30 of SEBI LODR Regulations, 2015, covers the quarter ended June 30, 2026. Revenue of Rs 4.87 crore reflects a sequential decline attributed partly to a brief disruption in billing and dispatch arising from an ERP system implementation in the final five days of the quarter, which pushed sales into Q2FY27. Executive Director Sunil Mundra noted that absent this disruption, reported revenue would have been modestly higher.
On the HPMC segment, the company cited erratic demand in the US market and uncertainty around duty structures as the basis for temporarily converting one HPMC line to gelatine. The API business recorded mixed performance, with the Chinese yuan appreciation and Indian rupee depreciation creating headwinds for African export volumes. The first batch under a contract manufacturing agreement with Fermbox Bio commenced in August 2026, and a new contract manufacturing agreement was executed with a Mumbai-based client.
Impact on Investors
Investors will note that the company reported a loss after tax of Rs 5.74 crore in Q1FY27, marginally wider than the Rs 5.55 crore loss in Q4FY26. The filing shows that EBITDA margins, while improved year-on-year by 159 basis points, contracted 28 basis points sequentially. The disclosed ERP-related billing disruption and HPMC line conversion are specific operational factors shareholders will observe when assessing the reported quarter's comparability with prior periods.
The disclosed WHO GMP audit expected by end of Q2FY27 represents a regulatory milestone for the API business. The filing indicates the company appointed a Chief Operating Officer for the API segment, a development the disclosed terms describe as part of scaling that business. No dividend was declared for this quarter.
Sector / Market Context
India's pharmaceutical capsule manufacturing sector serves both domestic and export markets, with hard capsule shells used widely across generic drug formulations. According to industry data cited by the Pharmaceuticals Export Promotion Council of India, pharmaceutical exports remain a significant contributor to India's overall merchandise trade, providing a broad demand context for capsule manufacturers serving API and formulation clients.